烧伤后侵袭性真菌感染的研究进展

蔡悦; 程兴; 詹剑华; 罗锦花; 廖文强

doi:10.3760/cma.j.cn501225-20220523-00199

烧伤后侵袭性真菌感染的研究进展

doi: 10.3760/cma.j.cn501225-20220523-00199

南昌大学第一附属医院烧伤整形与创面修复医学中心，南昌　　330006

基金项目:

江西省科技计划项目 20171BBG70061, 20202BBG73020

详细信息

通讯作者:
詹剑华，Email：zjhseasky@163.com

计量
- 文章访问数: 303
- HTML全文浏览量: 75
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2022-05-23

Research advances on invasive fungal infections after burns

Medical Center of Burn Plastic and Wound Repair, the First Affiliated Hospital of Nanchang University, Nanchang 330006, China

Funds:

Science and Technology Plan Project of Jiangxi Province of China 20171BBG70061, 20202BBG73020

More Information

Corresponding author: Zhan Jianhua, Email: zjhseasky@163.com

摘要

摘要: 侵袭性真菌感染（IFI）是烧伤患者严重的并发症之一。近年来广谱抗生素的逐步研发应用致使菌群严重失调，而抗真菌药物的广泛预防性使用则导致耐药真菌日渐增加。IFI临床治疗难度大，预后差，IFI所致烧伤患者的病死率逐年上升。该文从烧伤后IFI的流行病学特点、相关危险因素、诊断方法及治疗进展方面进行综述，旨在为烧伤后IFI的预防和治疗提供新的思路及依据。
- 烧伤 /
- 侵袭性真菌感染 /
- 危险因素 /
- 流行病学特点
Abstract: Invasive fungal infection (IFI) is one of the serious complications in burn patients. The gradual development and application of broad-spectrum antibiotics in recent years has led to a serious dysbiosis of the flora, while the widespread prophylactic use of antifungal drugs has led to an increasing number of drug-resistant fungi. The clinical treatment of IFI is difficult and the prognosis is poor. The mortality of burn patients caused by IFI is increasing year by year. This paper reviews the epidemiologic characteristics, related risk factors, diagnostic methods, and treatment progress of IFI after burns, aiming to provide new ideas and reference for the prevention and treatment of IFI after burns.
- Burns /
- Invasive fungal infections /
- Risk factors /
- Epidemiologic characteristics
所有作者均声明不存在利益冲突

HTML全文

参考文献(45)

[1]	《中华烧伤杂志》编辑委员会.烧伤侵袭性真菌感染诊断与防治指南(2012版)[J].中华烧伤杂志,2012,28(2):81-86.DOI: 10.3760/cma.j.issn.1009-2587.2012.02.001.
[2]	LuoG,TanJ,PengY,et al.Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013[J/OL].Burns Trauma,2014,2(2):45-52[2022-05-23].https://pubmed.ncbi.nlm.nih.gov/27602362/.DOI: 10.4103/2321-3868.130182.
[3]	PalackicA,PoppD,TapkingC,et al.Fungal infections in burn patients[J].Surg Infect (Larchmt),2021,22(1):83-87.DOI: 10.1089/sur.2020.299.
[4]	SoboutiB,DahmardeheiM,FallahS,et al.Candidemia in pediatric burn patients: risk factors and outcomes in a retrospective cohort study[J].Curr Med Mycol,2020,6(3):33-41.DOI: 10.18502/cmm.6.3.4663.
[5]	RafikA,DiouriM,BahecharN,et al.Epidemiology of nosocomial fungal infections in the National Center for Burns in Casablanca, Morocco[J].Ann Burns Fire Disasters,2016,29(2):90-93.
[6]	Badino VarelaMG,SnitmanGV,LandaburuMF,et al.Fungal identification in burn patients. A retrospective study and risk factors[J].Medicina (B Aires),2021,81(5):780-785.
[7]	ZhouJ,TanJ,GongY,et al.Candidemia in major burn patients and its possible risk factors: a 6-year period retrospective study at a burn ICU[J].Burns,2019,45(5):1164-1171.DOI: 10.1016/j.burns.2019.01.005.
[8]	张成,龚雅利,罗小强,等.重度烧伤患者真菌血流感染的病原学特征分析[J].中华烧伤杂志,2020,36(1):37-41.DOI: 10.3760/cma.j.issn.1009-2587.2020.01.007.
[9]	VaeziA,FakhimH,KhodavaisyS,et al.Epidemiological and mycological characteristics of candidemia in Iran: a systematic review and meta-analysis[J].J Mycol Med,2017,27(2):146-152.DOI: 10.1016/j.mycmed.2017.02.007.
[10]	TadecL,TalarminJP,GastinneT,et al.Epidemiology, risk factor, species distribution, antifungal resistance and outcome of candidemia at a single French hospital: a 7-year study[J].Mycoses,2016,59(5):296-303.DOI: 10.1111/myc.12470.
[11]	RodriguezL,BustamanteB,HuarotoL,et al.A multi-centric study of Candida bloodstream infection in Lima-Callao, Peru: species distribution, antifungal resistance and clinical outcomes[J].PLoS One,2017,12(4):e0175172.DOI: 10.1371/journal.pone.0175172.
[12]	Van BangBN,Thanh XuanN,XuanQuang D,et al.Prevalence, species distribution, and risk factors of fungal colonization and infection in patients at a burn intensive care unit in Vietnam[J].Curr Med Mycol,2020,6(3):42-49.DOI: 10.18502/cmm.6.3.4664.
[13]	DevauchelleP,JeanneM,FréalleE.Mucormycosis in burn patients[J].J Fungi (Basel),2019,5(1):25.DOI: 10.3390/jof5010025.
[14]	MontazeriA,ZandiH,TeymouriF,et al.Microbiological analysis of bacterial and fungal bioaerosols from burn hospital of Yazd (Iran) in 2019[J].J Environ Health Sci Eng,2020,18(2):1121-1130.DOI: 10.1007/s40201-020-00531-7.
[15]	MaurelV,DenisB,CambyM,et al.Outcome and characteristics of invasive fungal infections in critically ill burn patients: a multicenter retrospective study[J].Mycoses,2020,63(6):535-542.DOI: 10.1111/myc.13068.
[16]	MitchellTA,HardinMO,MurrayCK,et al.Mucormycosis attributed mortality: a seven-year review of surgical and medical management[J].Burns,2014,40(8):1689-1695.DOI: 10.1016/j.burns.2014.03.013.
[17]	HortaR,TomazD,EgiptoP,et al.The outcome of fungal infections in a burn intensive care unit: a study of 172 patients[J].Ann Burns Fire Disasters,2020,33(2):101-106.
[18]	金少华,李传吉,张龙,等.成批烧伤患者感染病原菌情况及耐药性分析[J].中华烧伤杂志,2015,31(4):300-303.DOI: 10.3760/cma.j.issn.1009-2587.2015.04.018.
[19]	LinYL,ChenIC,YenJH,et al.Invasive candidiasis in hospitalized patients with major burns[J].J Pers Med,2022,12(1):47.DOI: 10.3390/jpm12010047.
[20]	WhaleySG,BerkowEL,RybakJM,et al.Azole antifungal resistance in Candida albicans and emerging non-albicans Candida species[J].Front Microbiol,2017,7:2173.DOI: 10.3389/fmicb.2016.02173.
[21]	El-Ganiny AM,Yossef NE,Kamel HA.Prevalence and antifungal drug resistance of nosocomial Candida species isolated from two university hospitals in Egypt[J].Curr Med Mycol,2021,7(1):31-37.DOI: 10.18502/cmm.7.1.6181.
[22]	TortoranoAM,PrigitanoA,MorroniG,et al.Candidemia: evolution of drug resistance and novel therapeutic approaches[J].Infect Drug Resist,2021,14:5543-5553.DOI: 10.2147/IDR.S274872.
[23]	KhairatSM,SayedAM,NabihM,et al.Prevalence of Candida blood stream infections among children in tertiary care hospital: detection of species and antifungal susceptibility[J].Infect Drug Resist,2019,12:2409-2416.DOI: 10.2147/IDR.S196972.
[24]	刘正印,王贵强,朱利平,等.隐球菌性脑膜炎诊治专家共识[J].中华内科杂志,2018,57(5):317-323.DOI: 10.3760/cma.j.issn.0578-1426.2018.05.003.
[25]	McCartyTP,LuethyPM,BaddleyJW,et al.Clinical utility of antifungal susceptibility testing[J].JAC Antimicrob Resist,2022,4(3):dlac067.DOI: 10.1093/jacamr/dlac067.
[26]	CornelyOA,Alastruey-IzquierdoA,ArenzD,et al.Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J].Lancet Infect Dis,2019,19(12):e405-e421.DOI: 10.1016/S1473-3099(19)30312-3.
[27]	StruckMF,GilleJ.Fungal infections in burns: a comprehensive review[J].Ann Burns Fire Disasters,2013,26(3):147-153.
[28]	OkunoE,JarrosIC,Bonfim-MendonçaPS,et al.Candida parapsilosis isolates from burn wounds can penetrate an acellular dermal matrix[J].Microb Pathog,2018,118:330-335.DOI: 10.1016/j.micpath.2018.03.058.
[29]	WhiteLP,PriceJS.Recent advances and novel approaches in laboratory-based diagnostic mycology[J].J Fungi (Basel),2021,7(1):41.DOI: 10.3390/jof7010041.
[30]	Freeman WeissZ,LeonA,KooS.The evolving landscape of fungal diagnostics, current and emerging microbiological approaches[J].J Fungi (Basel),2021,7(2):127.DOI: 10.3390/jof7020127.
[31]	VatanshenassanM,BoekhoutT,Lass-FlörlC,et al.Proof of concept for MBT ASTRA, a rapid matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)-based method to detect caspofungin resistance in Candida albicans and Candida glabrata[J].J Clin Microbiol,2018,56(9):e00420-18.DOI: 10.1128/JCM.00420-18.
[32]	MondayLM,Parraga AcostaT,AlangadenG.T2Candida for the diagnosis and management of invasive Candida infections[J].J Fungi (Basel),2021,7(3):178.DOI: 10.3390/jof7030178.
[33]	OliveiraLVN,WangR,SpechtCA,et al.Vaccines for human fungal diseases: close but still a long way to go[J].NPJ Vaccines,2021,6(1):33.DOI: 10.1038/s41541-021-00294-8.
[34]	张婷婷,孙玲洁,冯四洲.艾沙康唑治疗侵袭性真菌病的临床研究进展[J].中国感染与化疗杂志,2022,22(3):360-365.DOI: 10.16718/j.1009-7708.2022.03.023.
[35]	HoeniglM,SpruteR,EggerM,et al.The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin[J].Drugs,2021,81(15):1703-1729.DOI: 10.1007/s40265-021-01611-0.
[36]	ThompsonGR,SorianoA,SkoutelisA,et al.Rezafungin versus caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis: the STRIVE trial[J].Clin Infect Dis,2021,73(11):e3647-e3655.DOI: 10.1093/cid/ciaa1380.
[37]	ShawKJ,IbrahimAS.Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections[J].J Fungi (Basel),2020,6(4):239.DOI: 10.3390/jof6040239.
[38]	GhannoumM,LongL,LarkinEL,et al.Evaluation of the antifungal activity of the novel oral glucan synthase inhibitor SCY-078, singly and in combination, for the treatment of invasive aspergillosis[J].Antimicrob Agents Chemother,2018,62(6):e00244-18.DOI: 10.1128/AAC.00244-18.
[39]	ZhangJ,LiuH,XiL,et al.Antifungal susceptibility profiles of olorofim (formerly F901318) and currently available systemic antifungals against mold and yeast phases of Talaromyces marneffei[J].Antimicrob Agents Chemother,2021,65(6):e00256-21.DOI: 10.1128/AAC.00256-21.
[40]	NaritaK,AsanoK,NaitoK,et al.222-nm UVC inactivates a wide spectrum of microbial pathogens[J].J Hosp Infect,2020,105(3):459-467.DOI: 10.1016/j.jhin.2020.03.030.
[41]	ZhangY,ZhuY,ChenJ,et al.Antimicrobial blue light inactivation of Candida albicans: in vitro and in vivo studies[J].Virulence,2016,7(5):536-545.DOI: 10.1080/21505594.2016.1155015.
[42]	庞家胤,和亚雄,郑梦雪,等.光动力抗菌疗法对多重耐药铜绿假单胞菌体外杀伤作用的研究[J].第三军医大学学报,2021,43(7):599-605.DOI: 10.16016/j.1000-5404.202012135.
[43]	TanakaJL,Costa-OrlandiCB,BurdBS,et al.Natural rubber dressing loaded with silver sulfadiazine for the treatment of burn wounds infected with Candida spp[J].Int J Biol Macromol,2021,189:597-606.DOI: 10.1016/j.ijbiomac.2021.08.102.
[44]	NiziołM,PalecznyJ,JunkaA,et al.3D printing of thermoresponsive hydrogel laden with an antimicrobial agent towards wound healing applications[J].Bioengineering (Basel),2021,8(6):79.DOI: 10.3390/bioengineering8060079.
[45]	KatzT,WasiakJ,ClelandH,et al.Incidence of non-candidal fungal infections in severe burn injury: an Australian perspective[J].Burns,2014,40(5):881-886.DOI: 10.1016/j.burns.2013.11.025.